MNCs Discuss China’s Pharmaceutical Market Outlook
This article was originally published in PharmAsia News
The recent 2008 new pharmaceutical business development forum in Qingdao, China, organized by Pfizer Investment, aimed to provide a platform for exchanging knowledge and analyses for the drug community. Pharmaceutical giants such as Xian-Janssen, Johnson & Johnson, Bayer and Novartis shared their business development strategies and market outlook for China, with participation from McKinsey and PricewaterhouseCoopers. Besides continuing to speed up new drug development, launch and patent application, MNCs are shifting from the previous tradition of setting up plants for production, to pursuing mergers and acquisitions to build a firm foothold in the local market. All seek new collaborative approaches to tap the vast potential of the country, according to forum participants. (Click here for more - Chinese Language)
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.